


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Mesens *et al.*

Appl. No.: 09/578,908

Filed: May 26, 2000

For: **Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles**

Art Unit: 1626

Examiner: Unassigned

Atty. Docket: 00166.0051.US05

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§1.56, 1.97 and 1.98.

Copies of documents were previously cited or submitted in Applicants' 35 U.S.C. § 120 priority Application No. **09/252,486 (Patent No. 6,110,921)**, filed **February 18, 1999**, Application No. **09/005,549 (Patent No. 5,965,168)**, filed **January 12, 1998**, Application No. **08/808,261 (Patent No. 5,770,231)**, filed **February 28, 1997** and priority Application No. **08/154,403**, filed **November 19, 1993**. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449 and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0740 referencing docket number 00166.0051.US05.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Andrea G. Reister". The signature is fluid and cursive, with a large loop at the end.

Andrea G. Reister (Reg. No. 36,253)

Date: October 11, 2000

COVINGTON & BURLING
1201 Pennsylvania Avenue, N.W.
Washington, D.C. 20004-2401
(202) 662-6000